Research progress of sotagliflozin in treatment of cardiovascular complications of patients with type 2 diabetes mellitus

doi:10.3760/cma.j.issn.1007-1245.2024.13.006

Abstract

Abstract:

The incidence of type 2 diabetes mellitus (T2DM) is increasing, and its development can result in several complications, including cardiac, renal, vascular, and neurological problems. Cardiovascular complications are the leading cause of death in patients with T2DM. Sotagliflozin, a dual SGLT inhibitor, may reduce cardiovascular complications, and improve cardiac outcome and patients' survival rate.

Key words:

Type 2 diabetes mellitus, Cardiovascular complications, Sotagliflozin, Progress

摘要：

2型糖尿病发病率逐年递增，随着病情发展可能出现心脏、肾脏、血管、神经等方面的并发症，其中心血管并发症是2型糖尿病患者死亡的重要原因。钠-葡萄糖共转运蛋白双重抑制剂索格列净可以减少2型糖尿病患者心血管并发症的发生，并改善心脏预后，提高患者生存率。

关键词:

2型糖尿病, 心血管并发症, 索格列净, 进展

Wang Xia, Zhang Lingyun, Song Shoujun.

Research progress of sotagliflozin in treatment of cardiovascular complications of patients with type 2 diabetes mellitus [J]. International Medicine and Health Guidance News, 2024, 30(13): 2141-2144.

王霞张凌云宋守君.

索格列净治疗2型糖尿病患者心血管并发症的研究进展 [J]. 国际医药卫生导报, 2024, 30(13): 2141-2144.

References

[1] Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract,2022,183:109119.DOI:10.1016/j.diabres.2021.109119.
[2] Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1101.DOI:10.1056/NEJMoa0908292.
[3] Zoccali C, Mark PB, Sarafidis P, et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease[J].Nat Rev Nephrol,2023,19(11):733-746.DOI:10.1038/s41581-023-00747-4.
[4] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J].J Am Coll Cardiol,2022,79(17):1757-1780.DOI:10.1016/j.jacc.2021.12.011.
[5] Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives[J].Cardiovasc Diabetol,2019,18(1):20.DOI:10.1186/s12933-019-0828-y.
[6] Song P, Onishi A, Koepsell H, et al. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus[J].Expert Opin Ther Targets,2016,20(9):1109-1125.DOI:10.1517/14728222.2016.1168808.
[7] Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor[J].Diab Vasc Dis Res,2015,12(2):101-110.DOI:10.1177/1479164114563304.
[8] Zhang Q, Zhou S, Liu L. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis[J].Diabetol Metab Syndr,2023,15(1):118.DOI:10.1186/s13098-023-01092-z.
[9] Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis, prevention and treatment[J].Clin Exp Hypertens,2004,26(7-8):621-628.DOI:10.1081/ceh-200031945.
[10] Ninomiya T, Kubo M, Doi Y, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the hisayama study[J].Stroke,2007,38(7):2063-2069.DOI:10.1161/STROKEAHA.106.479642.
[11] Ohishi M. Hypertension with diabetes mellitus: physiology and pathology[J].Hypertens Res,2018,41(6):389-393.DOI:10.1038/s41440-018-0034-4.
[12] Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease[J].Hypertension,2021,78(5):1197-1205.DOI:10.1161/HYPERTENSIONAHA.121.17981.
[13] Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease[J].Circ Res,2020,126(11):1526-1548.DOI:10.1161/CIRCRESAHA.119.316065.
[14] Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American heart association[J].Circulation,2020,141(19):e779-e806.DOI:10.1161/CIR.0000000000000766.
[15] Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications[J].Hypertens Res,2018,41(3):147-156.DOI:10.1038/s41440-017-0008-y.
[16] Zarkasi KA, Abdul Murad NA, Ahmad N, et al. Coronary heart disease in type 2 diabetes mellitus: genetic factors and their mechanisms, gene-gene, and gene-environment interactions in the asian populations[J].Int J Environ Res Public Health,2022,19(2):647.DOI:10.3390/ijerph19020647.
[17] Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation[J].Cardiovasc Diabetol,2018,17(1):57.DOI:10.1186/s12933-018-0703-2.
[18] Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus[J].Circ Res,2019,124(1):121-141.DOI:10.1161/CIRCRESAHA.118.311371.
[19] Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study[J].BMJ,2000,321(7258):405-412.DOI:10.1136/bmj.321.7258.405.
[20] 罗静. 2型糖尿病胰岛素抵抗与心血管疾病的研究进展[J]. 公共卫生与预防医学,2023,34(5):125-128.DOI:10.3969/j.issn.1006-2483.2023.05.028.
[21] Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity[J].Circ Res,2018,122(4):624-638.DOI:10.1161/CIRCRESAHA.117.311586.
[22] Arnold SV, Echouffo-Tcheugui JB, Lam CSP, et al. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. insights from the diabetes collaborative registry (DCR)[J].Am Heart J,2018,203:25-29.DOI:10.1016/j.ahj.2018.05.016.
[23] Sung JY, Lee KH, Jun JH, et al. Changes in peripapillary microvasculature in patients with type 2 diabetes patients: effect of systemic hypertension[J].Sci Rep,2023,13(1):19459.DOI:10.1038/s41598-023-46374-8.
[24] Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J].Circulation,2016,134(10):752-772.DOI:10.1161/CIRCULATIONAHA.116.021887.
[25] Wu J, Zhao X, Chen H, et al. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: an updated meta-analysis of randomized controlled trials[J].J Diabetes Complications,2022,36(12):108352.DOI:10.1016/j.jdiacomp.2022.108352.
[26] Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure[J].N Engl J Med,2021,384(2):117-128.DOI:10.1056/NEJMoa2030183.
[27] Szarek M, Bhatt DL, Steg PG, et al. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure : a randomized trial[J].Ann Intern Med,2021,174(8):1065-1072.DOI:10.7326/M21-0651.
[28] 郭一丁.达格列净辅助治疗老年心力衰竭合并T2DM患者的效果[J].广州医药,2023,54(3):101-104.DOI:10.3969/j.issn.1000-8535.2023.03.019.
[29] Gong Y, Kong B, Shuai W, et al. Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction[J].Eur J Pharmacol,2022,936:175357.DOI:10.1016/j.ejphar.2022.175357.